Percutaneous therapies for tricuspid regurgitation

Erin A. Fender, Rick A. Nishimura, David Holmes

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Chronic tricuspid valve regurgitation is usually associated with left-sided heart disease or pulmonary hypertension. Although severe tricuspid valve regurgitation carries a poor prognosis, isolated surgery is rarely performed due to high in-hospital mortality and an unclear impact on long term survival. The lack of adequate surgical treatment has resulted in a large population of patients with an unmet clinical need. Areas covered: Transcatheter therapies have revolutionized the management of high risk patients with left-sided valvular disease, and have sparked interest in translating minimally invasive therapies to the tricuspid valve. Here we will discuss some of the challenges of percutaneous tricuspid interventions, and review the novel therapies which are in early development. Expert commentary: Transcatheter therapies for the tricuspid valve are in early development, and are not yet appropriate for clinical use. In select non-surgical patients transcatheter devices may ultimately provide a therapeutic approach to palliate symptoms. However, further studies are needed to demonstrate both efficacy and safety before these devices are introduced to clinical practice.

Original languageEnglish (US)
Pages (from-to)37-48
Number of pages12
JournalExpert review of medical devices
Volume14
Issue number1
DOIs
StatePublished - Jan 2 2017

Fingerprint

Tricuspid Valve Insufficiency
Surgery
Tricuspid Valve
Therapeutics
Protective Devices
Risk Management
Hospital Mortality
Pulmonary Hypertension
Heart Diseases
Equipment and Supplies
Survival
Population

Keywords

  • Percutaneous valve repair
  • transcatheter valve replacement
  • tricuspid regurgitation

ASJC Scopus subject areas

  • Surgery
  • Biomedical Engineering

Cite this

Percutaneous therapies for tricuspid regurgitation. / Fender, Erin A.; Nishimura, Rick A.; Holmes, David.

In: Expert review of medical devices, Vol. 14, No. 1, 02.01.2017, p. 37-48.

Research output: Contribution to journalReview article

Fender, Erin A. ; Nishimura, Rick A. ; Holmes, David. / Percutaneous therapies for tricuspid regurgitation. In: Expert review of medical devices. 2017 ; Vol. 14, No. 1. pp. 37-48.
@article{82b6d20fcef741d19973b842eb7d499b,
title = "Percutaneous therapies for tricuspid regurgitation",
abstract = "Introduction: Chronic tricuspid valve regurgitation is usually associated with left-sided heart disease or pulmonary hypertension. Although severe tricuspid valve regurgitation carries a poor prognosis, isolated surgery is rarely performed due to high in-hospital mortality and an unclear impact on long term survival. The lack of adequate surgical treatment has resulted in a large population of patients with an unmet clinical need. Areas covered: Transcatheter therapies have revolutionized the management of high risk patients with left-sided valvular disease, and have sparked interest in translating minimally invasive therapies to the tricuspid valve. Here we will discuss some of the challenges of percutaneous tricuspid interventions, and review the novel therapies which are in early development. Expert commentary: Transcatheter therapies for the tricuspid valve are in early development, and are not yet appropriate for clinical use. In select non-surgical patients transcatheter devices may ultimately provide a therapeutic approach to palliate symptoms. However, further studies are needed to demonstrate both efficacy and safety before these devices are introduced to clinical practice.",
keywords = "Percutaneous valve repair, transcatheter valve replacement, tricuspid regurgitation",
author = "Fender, {Erin A.} and Nishimura, {Rick A.} and David Holmes",
year = "2017",
month = "1",
day = "2",
doi = "10.1080/17434440.2017.1268912",
language = "English (US)",
volume = "14",
pages = "37--48",
journal = "Expert Review of Medical Devices",
issn = "1743-4440",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Percutaneous therapies for tricuspid regurgitation

AU - Fender, Erin A.

AU - Nishimura, Rick A.

AU - Holmes, David

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Introduction: Chronic tricuspid valve regurgitation is usually associated with left-sided heart disease or pulmonary hypertension. Although severe tricuspid valve regurgitation carries a poor prognosis, isolated surgery is rarely performed due to high in-hospital mortality and an unclear impact on long term survival. The lack of adequate surgical treatment has resulted in a large population of patients with an unmet clinical need. Areas covered: Transcatheter therapies have revolutionized the management of high risk patients with left-sided valvular disease, and have sparked interest in translating minimally invasive therapies to the tricuspid valve. Here we will discuss some of the challenges of percutaneous tricuspid interventions, and review the novel therapies which are in early development. Expert commentary: Transcatheter therapies for the tricuspid valve are in early development, and are not yet appropriate for clinical use. In select non-surgical patients transcatheter devices may ultimately provide a therapeutic approach to palliate symptoms. However, further studies are needed to demonstrate both efficacy and safety before these devices are introduced to clinical practice.

AB - Introduction: Chronic tricuspid valve regurgitation is usually associated with left-sided heart disease or pulmonary hypertension. Although severe tricuspid valve regurgitation carries a poor prognosis, isolated surgery is rarely performed due to high in-hospital mortality and an unclear impact on long term survival. The lack of adequate surgical treatment has resulted in a large population of patients with an unmet clinical need. Areas covered: Transcatheter therapies have revolutionized the management of high risk patients with left-sided valvular disease, and have sparked interest in translating minimally invasive therapies to the tricuspid valve. Here we will discuss some of the challenges of percutaneous tricuspid interventions, and review the novel therapies which are in early development. Expert commentary: Transcatheter therapies for the tricuspid valve are in early development, and are not yet appropriate for clinical use. In select non-surgical patients transcatheter devices may ultimately provide a therapeutic approach to palliate symptoms. However, further studies are needed to demonstrate both efficacy and safety before these devices are introduced to clinical practice.

KW - Percutaneous valve repair

KW - transcatheter valve replacement

KW - tricuspid regurgitation

UR - http://www.scopus.com/inward/record.url?scp=85008422931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008422931&partnerID=8YFLogxK

U2 - 10.1080/17434440.2017.1268912

DO - 10.1080/17434440.2017.1268912

M3 - Review article

C2 - 27918213

AN - SCOPUS:85008422931

VL - 14

SP - 37

EP - 48

JO - Expert Review of Medical Devices

JF - Expert Review of Medical Devices

SN - 1743-4440

IS - 1

ER -